In cooperation with



Hyperprolactinemia is one of the most common endocrine disorders of the hypothalamic-pituitary-axis and most commonly caused by a prolactinoma. It is treated almost exclusively with dopamine agonists. This is also true for macroprolactinomas. Surgery or radiotherapy are reserved for exceptional cases only. »Over-surveillance« (i. e. repeated MRT and perimetry) and »over-treatment« (i. e. surgery, life-long medical treatment) should be avoided. This article discusses the causes of hyperprolactinemia, the diagnostic steps and the current recommendations for the treatment of hyperprolactinemia. The most important changes in the recent guidelines recommendations are that Cabergolin is now the »treatment of choice«, even in infertility patients and that in pregnancy the medical treatment even for macroprolactinomas can be interrupted, if they have been treated successfully at least for one year with dopaminagonists.

CME Prakt Fortbild Gynakol Geburtsmed Gynakol Endokrinol 2016; 12(1): 4–22

Hyperprolactinemia, prolactinoma, diagnostic, therapy

Julia Bartley
Kinderwunschzentrum an der Gedächtniskirche, Berlin
Reviewer: Heinz G. Bohnet, Hamburg,
und Thilo Schill, Hannover

Bartley J. Hyperprolaktinämie … Gynakol Geburtsmed Gynakol Endokrinol 2016; 12(1): 4–22 publiziert 31.03.2016 ©akademos Wissenschaftsverlag 2016 ISSN 1614-8533